The pancreas arises from Pdx1-expressing progenitors in developing foregut endoderm in early embryo. Expression of Ngn3 and NeuroD1 commits the cells to form endocrine pancreas, and to differentiate into subsets of cells that constitute islets of Langerhans. β-cells in the islets transcribe gene-encoding insulin, and subsequently process and secrete insulin, in response to circulating glucose. Dysfunction of β-cells has profound metabolic consequences leading to hyperglycemia and diabetes mellitus. β-cells are destroyed via autoimmune reaction in type 1 diabetes (T1D). Type 2 diabetes (T2D), characterized by impaired β-cell functions and reduced insulin sensitivity, accounts for 90% of all diabetic patients. Islet transplantation is a promising treatment for T1D. Pluripotent stem cells provide an unlimited cell source to generate new β-cells for patients with T1D. Furthermore, derivation of induced pluripotent stem cells (iPSCs) from patients captures "disease-in-a-dish" for autologous cell replacement therapy, disease modeling, and drug screening for both types of diabetes. This review highlights essential steps in pancreas development, and potential stem cell applications in cell regeneration therapy for diabetes mellitus.
and Foxa2, and later differentiate to form the epithelium of the primitive gut tube that gives rise to gastrointestinal and respiratory tracts, and organs of digestive tracts. The posterior gut endoderm develops into mid-and hindgut, that later give rise to the intestine. Pdx1-expressing cells are detected in both anterior and posterior foregut endoderm, which develop into ventral and dorsal pancreas respectively [2] .
Fibroblast growth factor (FGF) signaling controls anterior-posterior axis formation during endoderm development in the embryo. In vivo, cardiac mesoderm-secreted FGF2 patterns the ventral foregut into liver and lung [3] , whereas FGF2 secreted by notochord represses endodermal sonic hedgehog (SHH), and permits pancreas development [4] . Using human embryonic stem cells (HESCs) as an in vitro model, Ameri et al. showed that FGF2 is involved in foregut and hindgut specification, in a concentration-dependant manner [5] . In their study, low doses of FGF2 promoted a hepatic fate, while high doses induced anterior foregut and small intestinal cell develop-
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Generating definitive endoderm and pancreatic endocrine cells from embryonic stem cells (ESCs)
Various approaches have been tested to induce DE from embryonic stem cells (ESCs). Using a Brachyury-eGFP (Bry-eGFP) mouse ESC reporter line, Kubo et al. defined a requirement for a member of the transforming growth factor β (TGF-β) family, activin A in the induction of this early lineage [9] . Bry-eGFP + cells, derived from differentiating embryoid bodies (EBs), gave rise to both mesoderm and endoderm populations. [11] . During activin A treatment, undifferentiated cells were transitioned though mesendodermal pathway, accompanied by the transient expression of BRACHYURY, N-CADHERIN, WNT3a and FGF4. Also, Wnt3a directly induced BRACHYURY expression, and elicited a rapid and highly efficient cellular progression through primitive streak to DE [12] . Remarkably, the activin A-induced DE specification is efficient only when insulin/insulin growth factor (IGF) signaling is reduced, and when phosphoinositide 3-kinase (PI3K) signaling is suppressed [13] . These DE cells could be isolated and enriched by fluorescence-activated cell sorting (FACS) for CXCR4-expressing cells. Similar to Yasunaga's finding, CXCR4 expression in activin A-treated cultures also distinguished DE from PrE cells.
In the absence of serum, or in very low serum concentration, experiments with human and mouse ESCs provided evidence for effective DE induction by activin A. Furthermore, activin A induction is concentration-dependent. High concentration of activin A (50-100 ng/ml) is required for efficient DE induction [9, 14, 15] . The use of low activin A concentrations (5 -20 ng/ml) was sufficient to maintain undifferentiated feeder-free human ESCs in pluripotent state (Figure 1) . Whereas, intermediate levels of activin A (20-50 ng/ml) provoked differentiation to mesoderm lineage [16] . However, in monolayer cultures, expression of Gsc and other anterior markers can be inhibited by bone morphogenetic protein-4 (BMP4), which may prolong Brachyury expression and lead to subsequent mesoderm development [17] . Intriguingly, simultaneous exposure of HESCs, differentiated to intermediate levels of BMP4, and activin A (50 ng/ml each) supported DE differentiation, evidenced by increased PDX1 transcript expression in embryoid bodies.
SHH inhibitor and FGF10 have been used to prime DE cells to form cells characteristic of primitive gut tube. At this stage, DE cell markers were downregulated, while HNF1B and HNF4A expressions increased. Retinoic acid (RA), a 'posteriorizing factor' and Notch inhibitor was included next to promote posterior foregut and endocrine cell formation, while suppressing exocrine program. The use of exedin-4, IGF1, and HGF1, at the later stage of differentiation, increased the formation of all pancreatic hormone-producing cell types. However, the inclusion of various signaling inhibitors always resulted in prominent cell death in cultures, hindering continuous culture and downstream analysis (our own observations).
Co-culturing of mouse ESCs with primary hepatocytes also induced the formation of homogenous monolayer of DE-like cells [18] . These DE cells could be coaxed into endocrine pancreas by plating on Matrigel using SHH inhibitor and RA. The resulting cells were pancreatic endocrine cells, demonstrated by upregulation of Pdx1 transcript and protein levels. These cells were cocultured with cardiac microvascular endothelial cells and Notch inhibitor to prompt islet cell matu-ration. The outcome of this protocol is a large-scale generation of morphologically homogenous cultures that contain 60% cells co-expressing Pdx1 and C-peptide [18] . These findings have drawn two important conclusions: first, direct co-culture significantly increases Pdx1 and insulin production, compared to the use of conditioned medium or transwell indirect cultures. This suggests that cell-to-cell contact is a prerequisite for efficient pancreatic β-cell development. Second, direct coculture efficiently enhances cell survival, while the Notch signaling pathway is suppressed in the presence of various antagonists.
Screening of small molecule libraries is fast becoming an increasingly popular tool to unravel the various pathways that control lineage commitment in stem cells. Small molecules are low molecular weight organic compounds that have high affinity to biopolymers, such as protein and nucleic acid. Several researcher groups have discovered small molecules that increase the production of pancreatic progenitors from mouse and human ESCs. In most studies, activin A was first used to specifically induce DE cell formation. For [20, 21] . Studies with Pdx1-eGFP reporter line also confirmed that these DE cells were able to further differentiate into pancreatic progenitors. These chemically-induced DE cells were able to incorporate into the gut tube of mouse embryos in vivo, indicating full functional competency of the cells. However, it is unknown whether IDE1 and IDE2 mediate DE formation through mesendoderm induction. On the other hand, (-)-indolactam V (ILV) is also found to be a potent inducer of pancreatic progenitor formation from human ESCs. ILV activated protein kinase C (PKC) signaling, and specifically targeted at one stage of pancreatic development, by inducing Pdx1-expressing cells from gut tube endoderm [22] . PKC signaling is thus implicated in the induction and maintenance of Pdx1 + cells. The role of PKC agonists should further be exploited in generating pancreatic β-cells from DE and ESCs.
The protocol to generate islet cell types, especially β-cells from pancreatic endoderm, is less defined. In vivo, islet-like cell clusters, isolated from fetal pancreas obtained during second trimester, contain less than 10% β- 10 ng/ml activin A maintains undifferentiated ESCs in the presence of 10% serum. 100ng/ml activin A induces epithelial-tomesenchymal transition (EMT) only in serum-free (SF) cultures. EMT plays crucial roles in embryonic gastrulation, and gives rise to the mesoderm and endoderm [67] . FACS analysis shows the number of CXCR4-expressing cells in each culture condition.
cells. These insulin-producing β-cells are Ki67-positive and highly proliferative. Subsequently, they constitute 50% of cells found in adult islets [23, 24] . Human fetal β-cells are able to release insulin in response to secretagoues that elevate cAMP levels, but they secrete little or no insulin when challenged with glucose [25] . β-cells have also been derived from DE cells cultured in a differentiation cocktail consisting of FGF10, epidermal growth factor (EGF), VEGF, forskolin, HGF, and pancreatic polypeptide (PPY). The use of exedin 4, IGF1, and HGF resulted in insulinproducing cells that responded to β-cell secretagogues, but only minimally to glucose, indicating the immature status of the cells. However, Ngn3-and Nkx6.1-expressing pancreatic endoderm generated glucose-responsive endocrine and insulinproducing cells after transplantation into mice. Additionally, the use of FGF2/nicotinamide and transfer of differentiated cells to aggregate cultures was found to generate insulin-producing cells that responded to high glucose stimulation [26] . This finding suggests that in vivo maturation and reaggregation are necessary to generate glucose-responsive adult β-cells from human ESCs. Figure 2 summarizes specification, commitment, and DE formation of endocrine pancreas and β-cells from an undifferentiated stem cell population.
Genetic manipulation
Constitutive expression of pdx1 or pax4 in mouse ESCs promote differentiation of nestinpositive progenitors and insulin-producing cells. During in vitro differentiation, important changes in expression levels of pancreatic genes were detected in Pax4 + cells, and to a lesser extent, in Pdx1 + cells. IAPP, GLUT2, and insulin mRNA were upregulated in Pax4 + cells at a later stage of differentiation, although ngn3 expression remained constant, suggesting that ngn3 is upstream of pax4 expression [27] . Pax4 + cells also contained an increased level of intracellular insulin. When cultivated in 'Spinner' bioreactors these cells undergo histotypic maturation to yield spheroid islet-like clusters grown in suspension. Electron microscopy detected insulin secretory granules, a characteristic of β-cells in adult islets [28] . Moreover, Pax4 + cells were glucose-responsive, and were able to normalize blood glucose levels in streptozotocin (STZ)-treated diabetic mice.
Overexpression of Foxa2 or Pdx1 has minimal effect in promoting pancreatic differentiation in human ESCs. Surprisingly, Foxa2 upregulated PAX6 expression, a neuroectodermal marker in EBs. Pdx1 overexpression transiently upregulated NGN3 and NKX2.2 transcript expression, but did not induce insulin production even in later stages of differentiation. Pdx1 is required for pancreas morphogenesis in early embryo, and is downregulated during endocrine specification. [29] . These cells upregulated INSULIN, PDX1, GLUT2, and Prohormone convertase 1/3 (PC1/3) transcripts, contained Cpeptide, and responded to depolarizing concentration of KCl in a manner consistent with an action on voltage-gated Ca 2+ channel (VGCC) gene expression. Pax4 + cells are also found to potentiate the expression of VGCC genes associated with the endocrine pancreas, such as CACNA1A and CACNA1C [30] .
Transcriptional signaling during in vivo pancreas and islet development is a tightly controlled process. In most of the studies described above, transcription factors are overexpressed at a much earlier time. Nevertheless, precocious expression of these factors results in the formation of insulinproducing cells that retain expression of immature genes. This caveat can be circumvented by transiently and timely expressing genes of interest to promote formation of a desired cell type. For example, mouse EBs induced to express ngn3 were more sensitive to Notch-signaling inhibition. Therefore, they upregulated islet transcripts in differentiating cell population [31] . However, immunocytochemistry analysis revealed the predominant appearance of α-and somatostatinexpressing cells at the expense of other endocrine cells. On the other hand, conditional induction of cells. These insulin-producing β-cells are Ki67-positive and highly proliferative. Subsequently, they constitute 50% of cells found in adult islets [23, 24] . Human fetal β-cells are able to release insulin in response to secretagoues that elevate cAMP levels, but they secrete little or no insulin when challenged with glucose [25] . β-cells have also been derived from DE cells cultured in a differentiation cocktail consisting of FGF10, epidermal growth factor (EGF), VEGF, forskolin, HGF, and pancreatic polypeptide (PPY). The use of exedin 4, IGF1, and HGF resulted in insulinproducing cells that responded to β-cell secretagogues, but only minimally to glucose, indicating the immature status of the cells. However, Ngn3-and Nkx6.1-expressing pancreatic endoderm generated glucose-responsive endocrine and insulinproducing cells after transplantation into mice. Additionally, the use of FGF2/nicotinamide and transfer of differentiated cells to aggregate cultures was found to generate insulin-producing cells that responded to high glucose stimulation [26] . This finding suggests that in vivo maturation and reaggregation are necessary to generate glucose-responsive adult β-cells from human ESCs. Figure 2 summarizes specification, commitment, and DE formation of endocrine pancreas and β-cells from an undifferentiated stem cell population.
Overexpression of Foxa2 or Pdx1 has minimal effect in promoting pancreatic differentiation in human ESCs. Surprisingly, Foxa2 upregulated PAX6 expression, a neuroectodermal marker in EBs. Pdx1 overexpression transiently upregulated NGN3 and NKX2.2 transcript expression, but did not induce insulin production even in later stages of differentiation. Pdx1 is required for pancreas morphogenesis in early embryo, and is downregulated during endocrine specification. However, Pdx1 expression is upregulated, and is thereby maintained in mature β-cells for normal glucose homeostasis and regulation of insulin production. Thus, Pdx1 only exerts its effect in early pancreas development, but is not sufficient to induce the formation of pancreatic endocrine from human ESCs. Reporter lines created from stably transfected human ESCs revealed the appearance of Pdx1 -eGFP + cells in EBs, but insulin -eGFP + cells could not be detected at any stage of differentiation.
PAX4 is a switch between β-and α-cells. Based on its onset of activation prior to β-cell specification in developing pancreas, we have tested the function of Pax4 in committing human ESCs to differentiate into β-cells. Constitutive expression of Pax4 in human ESCs substantially enhanced their propensity to form β-like cells, even without culture manipulation [29] . These cells upregulated INSULIN, PDX1, GLUT2, and Prohormone convertase 1/3 (PC1/3) transcripts, contained Cpeptide, and responded to depolarizing concentration of KCl in a manner consistent with an action on voltage-gated Ca 2+ channel (VGCC) gene expression. Pax4 + cells are also found to potentiate the expression of VGCC genes associated with the endocrine pancreas, such as CACNA1A and CACNA1C [30] .
Transcriptional signaling during in vivo pancreas and islet development is a tightly controlled process. In most of the studies described above, transcription factors are overexpressed at a much earlier time. Nevertheless, precocious expression of these factors results in the formation of insulinproducing cells that retain expression of immature genes. This caveat can be circumvented by transiently and timely expressing genes of interest to promote formation of a desired cell type. For example, mouse EBs induced to express ngn3 were more sensitive to Notch-signaling inhibition. Therefore, they upregulated islet transcripts in differentiating cell population [31] . However, immunocytochemistry analysis revealed the predominant appearance of α-and somatostatinexpressing cells at the expense of other endocrine cells. On the other hand, conditional induction of Pdx1, using a Tet-Off inducible system in mouse EBs, resulted in upregulation of β-cell markers in a nestin-selection differentiation culture [32, 33] . Nevertheless, glucose responsiveness was not observed in these cells.
Cre-mediated induction of Sox17 in human ESCs gave rise to DE progenitors that upregulated HNF4a, CXCR4, and FOXA2 transcripts [34] . These Sox17-induced progenitors can be passaged and stably maintained in culture. As expected, these Sox17 + cells are multipotent. They can be directed to differentiate into hepatic and pancreatic lineages. In vivo studies revealed that teratoma formed by injection of Sox17 + cells contained a mixture of mesodermal and endodermal structures, with no evidence of ectoderm derivatives. They also gave rise to Pdx1 and insulinproducing pancreatic endocrine cells, when cultured in condition that favors pancreatic endocrine differentiation. Notably, activin A is not required during differentiation, possibly due to sustained endogenous Sox17 expression in the cells.
In future, a more deliberate genetic manipulation approach should be applied to induce pancreatic endocrine cells to undergo stepwise differentiation into more mature stages. The use of an in vitro inducible gene expression system to switch genes 'on and off' will faithfully recapitulate signaling cascades that regulate gene expression in vivo. Bernardo et al. have recently demonstrated that biphasic Pdx1 induction in mouse, and human, ESCs closely mimics pancreatic β-cell development [35] . Early and late Pdx1 induction, with intermediate withdrawal during in vitro differentiation, resulted in the highest upregulation of all islet endocrine transcripts expressed in cells differentiated from DE precursors. Despite this exciting finding, these cells expressed MAFB instead of MAFA, unlike adult β-cells. This feature is characteristic of partially differentiated pancreatic endocrine cell types [36] . Ultimately, timely expression of other critical transcription factors such as Pax4 and Nkx6.1 may be able to promote full maturation of these cells.
Effect of oxygen and glucose on embryonic pancreas differentiation
Earliest stages of human embryogenesis occur in a hypoxic, or even anoxic, environment [37] , a process implicated as critical for stem cells expansion. Recent evidence has identified a broader spectrum of stem cells, including ESCs, hematopoietic, mesenchymal, and neural stem cells influenced by differing oxygen concentration in culture [38] . At low oxygen tension (pO 2 ), cells exerted physiological response to ensure sufficient levels for oxygen-dependent processes. Hypoxiainducible factors (HIFs) were activated upon the exposure of cells to hypoxic condition, and regulated the expression of genes related with proliferation, differentiation, glycolysis, and apoptosis [39] . Hypoxia decreased the proliferation rate of embryonic pancreata [40] . In doing so, hypoxia induced HIF1α and Hes1 expression in embryonic pancreata, which in turn repressed Ngn3 expression, and prevented endocrine cell differentiation. On the other hand, there was a dramatic increase in the number of various islet cells when the embryonic pancreata were cultured in 80% O 2 . Thus, hypoxia can be induced in DE cells to expand pancreatic progenitors. Whereas, higher oxygen concentrations can be used at the later stage of differentiation to obtain β-cells.
In the adult pancreas, glucose is the major insulin secretagogue, and plays a role in β-cell proliferation [41] . Increased glucose concentration (10 mM) in adult islets leads to Pdx1 phosphorylation and nuclear translocation, where it binds to and transactivate the Insulin promoter [42, 43] . In embryonic pancreas primordium, endocrine cell development is activated in the presence of glucose in a dose-dependent manner (up to 10 mM), while acinar cell formation is glucose-independent [43] . In this context, glucose controls embryonic β-cell differentiation by regulating NeuroD expression, rather than stimulating expansion of pancreas progenitors. Also, hyperglycemia induced residual β-cell proliferation, and thus increased β-cell mass in an autoimmune diabetes model [44] . Similarly, glucose and FGF2 acted together to induce NEUROD and INSULIN expression in suspension cultured EBs from human ESCs, but it did not exert an effect on inducing earlier endocrine markers such as NGN3 [45] . Taken together, regulation of oxygen tension, and the use of glucose at different stages of differentiation, should be explored further to derive pancreatic endocrine cells and β-cells from mouse and human ESCs.
"Reprogramming" in existing pancreas cells
Earlier studies have shown that transdifferentiation of cells to other lineages is possible. For example, ectopic expression of pdx1 is sufficient to induce expression of insulin in mouse liver cells. Although transformed cells did not resemble functional β-cells in morphology, hyperglycemia in the host mice was reversed after in vivo transplanta-tion [46] . Others have demonstrated that fully differentiated exocrine cells activate endocrine programs, when dissociated and cultured in vitro in the presence of leukemia inhibitory factor (LIF), EGF, or nicotinamide [47] [48] [49] .
An emerging strategy for β-cell generation is inspired by the recent success of genetic manipulation and nuclear reprogramming in somatic cell types. By transiently expressing Ngn3, Pdx1, and MafA transcription factors with adenoviruses, 20% of mature pancreatic exocrine cells in adult mice were directly converted to β-cells [50] . Although these induced β-cells did not self-cluster, they remodeled local vasculature, secreted insulin, and ameliorated hyperglycemia. Thus, future work should focus on promoting aggregation of these transformed β-cells, which may fully restore glucose responsiveness in the mice. As pancreatic exocrine cells are the most abundant cell type in the pancreas, it is noteworthy that they are a potential surrogate source to generate β-cells for autologous cell replacement therapy in T1D patients.
Identification of novel transcription factors or cell surface markers may provide more information about pancreas development, and may significantly improve β-cell regeneration from stem cells. Partial pancreatectomy has been used as a model for pancreatic regeneration, as damaged pancreases secrete factors that stimulate differentiation or proliferation. Using a technique called suppression subtraction hybridization, which makes use of RNA extracted from injured and normal pancreas, Choi et al. have isolated twelve genes that were upregulated following partial pancreatectomy [51] . Several of these genes, namely GLUL, LGMN, and REG31 increased islet transcription factor expressions in Panc-1 and PC12 cell lines. Nevertheless, overexpression of these novel genes did not result in an increase in insulin-positive cells from mouse and human ESCs in vitro. However, overexpression of GLUL, LGMN, and REG31 may exert positive effects in generating β-cells from DE or pancreas endocrine cells. Thus, further studies on the roles of these novel genes are warranted.
Induced pluripotent stem cells and "disease-in-a-dish"
Derivation of induced pluripotent stem cells (iPSCs) has opened up opportunities to generate β-cells from individuals with diabetes mellitus. Human and mouse somatic cells can be reprogrammed to pluripotency by the introduction of two sets of transcription factors, either Oct4, Sox2, Klf4, and cMyc, or Oct4, Sox2, Nanog, and Lin28 (at 0.01% reprogramming efficiency) [52] [53] [54] . The inclusion of cMyc markedly enhanced iPSC generation, but also increased tumorigenicity in the resulting chimeras and progeny mice [55] . Recently, another Myc member, L-Myc was shown to specifically promote formation of fully reprogrammed iPSC colonies in human, and to promote germline transmission, but not tumor formation in the iPSC-derived mice [56] . Therefore, the use of L-Myc should be considered for future clinical applications.
Despite the remarkable similarity between iPSCs and ESCs, there is emerging evidence for subtle differences between these cells types. While some iPSC clones contribute poorly to chimeras [57] , different iPSC lines derived from different somatic cell types have distinctive in vitro and in vivo (teratoma) differentiation properties [58] . Several groups have recently demonstrated that iPSCs indeed retain epigenetic memory of their somatic cells of origin. To test this hypothesis, Kim et al. differentiated fibroblast-derived iPSCs (F-iPSCs) and blood cell-derived iPSCs (B-iPSCs) into hematopoietic colonies and osteoblasts. FiPSCs and B-iPSCs exhibited higher potential to form hematopoietic colonies and osteoblasts than mESCs and ESCs derived by nuclear transfer (ntESCs), respectively. This observation was surprising since their efficiency to differentiate into these two lineages is lower than that of mESCs and ntESCs [59, 60] . However, treatment with chromatin-modifying drugs, continuous passaging, differentiation, and serial reprogramming, largely attenuate the marked differences in differentiation propensity [60] . Hence, though iPSCs can be genetically identical, they are transcriptionally distinguishable based on their origin cell types. This is an important factor that can affect many differentiation protocols for disease modeling and patient-specific cell replacement therapies.
Novel techniques have been introduced over the years to generate transgene-free iPSCs suitable for use in clinical protocols. MicroRNAs have been shown to improve the reprogramming process, and to reduce heterogeneity in iPSC colonies [61] . Another advantage is that the use of recombinant proteins eliminated the risk of transgene integration in human iPSCs, even though the current success rate is 10-fold lower than that of the viral method [62] . Recent work, involving the use of a single excisable lentiviral "stem cell cassette" (STEMCCA), has produced mouse iPSCs that contributed to embryos with normal developmental morphology, and live chimeric mice [63] . This find-ing indicates that transgene-free iPSCs have improved the differentiation potential, and should be taken into account for the clinical application of iPSCs. Notably, multiple transgene-free diseasespecific human iPSC lines have been derived, using excisable STEMCCA from human patients with cystic fibrosis, sickle cell disease, and other lung-related diseases [64] .
Human iPSC lines from patients with other genetic diseases, including type 1 diabetes (T1D), have been derived [65] . Although not necessarily free of viral vectors, T1D-specific iPSCs (DiPSCs) provide a tool to study diabetes mellitus by modeling 'disease-in-a-dish'. DiPSCs were able to develop into cell types of three germ layers, following in vitro differentiation [66] . These DiPSCs responded to TGF-β/Nodal signaling, and were able to differentiate along the endodermal and pancreatic lineages, following treatment of activin A, FGF10, KAAD-Cyc, and RA. Hence, these cells can be used to generate new β-cells for the original donors. Nevertheless, one would expect diseasespecific iPSCs to closely mimic the phenotype of parental cells. Thus, long-term potential of DiPSCs to differentiate into pancreatic β-cells should be elucidated to investigate possible T1D onset later.
It is also mentionable that iPSCs provide a tool for toxicity testing and drug screening. Such applications may be useful in screening for potential chemicals, or environmental toxins, that contribute to the development of adult-onset type 2 diabetes (T2D), and maturity onset diabetes of the young (MODY). While stem cell is an obvious cell source for generating pancreatic β-cells to replace damaged cells for T1D patients, T2D is proven to be more difficult to treat, due to insulin resistance and relative insulin deficiency. Nonetheless, disease-specific human iPSCs provide a good model for investigating the effectiveness and potency of new drugs in treating T2D and MODY in preclinical applications.
Future prospects for stem cells in treating diabetes mellitus
Stem cells have shown promise to revolutionize the treatment of many degenerative diseases, including type 1 diabetes. Many studies provide evidence that ESC-and iPSC-derived β-cells in vitro are likely to mimic fetal β-cells, and are not fully functional. These cells could potentially be used to screen for new drugs to treat insulin secretory defects in T2D patients. Although patient-specific iPSCs are a potential source for autologous β-cell replacement therapy, there are transcriptional differences between ESC and iPSCs. Hence, further studies are required to ensure consistency and safety of pluripotent stem cells before they can be used in differentiation assays and future cell regenerative therapy.
